RxDoctor Payments Data

Hugh Burt, MD

Internal Medicine · Henderson, NVNPI 1972599371

Payments from drug & device makers

$1,463in general payments, 2019–2025

Across 52 payments — averaging $28.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$370
  • Medtronic$182
  • Mylan Specialty L.p.$142
  • Bayer$113
  • Amarin Pharma, Inc.$99
  • Novo Nordisk$86
  • plus $472 from 16 others

What the payments were for

  • Food & beverage$1,463100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,463 in reported general payments places this provider in the 75th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$46,241
Medicare patients
67
Services billed
393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin35$29,415
MounjaroTirzepatide24$23,566
EliquisApixaban12$19,122
OzempicSemaglutide13$11,596
TrulicityDulaglutide11$10,570
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen152$4,093
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen38$1,350
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,242
Tizanidine Hcl17$878
Pravastatin Sodium43$878
Atorvastatin Calcium75$707
Gabapentin50$640
Albuterol Sulfate HfaAlbuterol Sulfate15$598
Lisinopril64$593
Metoprolol Succinate29$541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$36$34,13635 claims
Boehringer IngelheimJardiance$17$29,41535 claims
PfizerEliquis$13$19,12212 claims
Novo NordiskOzempic$86$11,59613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →